BC Cancer Protocol Summary for Palliative Therapy of Extensive Stage Small Cell Lung Cancer (SCLC) with Oral Etoposide

**Protocol Code:** LUSCPOE

**Tumour Group:** Lung

**Contact Physician:** Dr. Christopher Lee

**ELIGIBILITY:**
- Extensive stage SCLC in patients refusing or unsuitable for combination chemotherapy
- Relapsed SCLC after prior chemotherapy with disease-free interval > 3 months

**TESTS:**
- Baseline: CBC & differential, platelets
- Before each treatment: CBC & differential, platelets

**PREMEDICATIONS:**
- See antiemetic guidelines for non-emetogenic chemotherapy (see protocol SCNAUSEA). Antiemetics are not usually required. Prescribe according to patient specific symptoms.

**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BC Cancer Administration Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etoposide</td>
<td>50 mg PO BID x 7 days</td>
<td>PO</td>
</tr>
</tbody>
</table>

- Repeat every 21 days x 4-6 cycles

**DOSE MODIFICATIONS:**

1. **Hematology**

<table>
<thead>
<tr>
<th>ANC (x 10^9/L)</th>
<th>Platelets (x 10^9/L)</th>
<th>Etoposide dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greater than or equal to 2.0 and Greater than or equal to 100</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>Less than 2.0 or Less than 100</td>
<td>Delay</td>
<td></td>
</tr>
</tbody>
</table>

2. **Neutropenic Sepsis:** reassess subsequent doses
PRECAUTIONS:

1. **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated aggressively.

Contact Dr. Christopher Lee or tumor group delegate @ (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

REFERENCES: